Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...